The first aim of the present study is the development of a new ruthenium(III) complex, belonging to NAMI-A
class, with a potentially high cytotoxic ability. The presence of a fully protected sugar moiety as ruthenium
ligand should increase the complex ability to cross cellular membranes. Furthermore, it sets this molecule in the
area of biocompatible agents as tumor drug. The second, more relevant, purpose is to verify the ruthenium
complexes activity after loading into liposomes. We reported the characterization and in vitro biological assays
of pyridine derivatives of ruthenium complexes loaded into Egg L-α-phosphatidylcholine cholesterol/DSPE-PEG
liposomes. Dynamic light scattering estimates that the sizes of all obtained liposomes are in the 100 nm range.
This value is suitable for in vivo use. The loading ability and release kinetic allowed selecting the best ratio
between the lipid fraction and metal to be tested in cellular experiments. The growth inhibitory effects of both
liposomal and free complex in PC-3 prostate cancer cell lines demonstrate a high cytotoxic ability of the liposome
entrapped ruthenium (III) complex suggesting additional role further the antimetastatic function.
|▼ Carbonic Anhydrase family as target for rational drug design|
|▼ Targeting Of Protein-Protein Interactions For Therapeutic Purposes Targeting delle interazioni proteina-proteina per scopi terapeutici|
|▼ Targeting Sam-Sam interactions mediated by EphA2 receptor: design and evaluation of peptide inhibitors Progettazione e validazione di peptidi inibitori delle interazioni Sam-Sam mediate dal recettore EphA2|
|▼ Analysis of Sam domain druggability through computational and experimental studies I domini Sam come bersagli farmacologici: studi computazionali e sperimentali|
|▼ Molecular imaging for personalized therapy in oncology|